Galectin Seeks Shareholder Nod to Nearly Double Authorized Shares to 250M
GALT sits 93% above its 52-week low of $2.025 on light trading volume (0.3× avg).
Summary
Galectin Therapeutics is asking shareholders to approve a 100 million share increase in authorized common stock and an additional 3 million shares for its equity incentive plan, while disclosing Chairman Uihlein's 49.4% ownership stake.
Key Events · Corporate Governance and Compliance · GALT
-
Authorized Share Increase Proposed
Proposal 2 seeks to increase authorized common shares from 150,000,000 to 250,000,000, adding 100 million shares for potential future issuance.
-
Equity Plan Expansion
Proposal 3 would reserve an additional 3,000,000 shares under the 2019 Omnibus Equity Incentive Plan, increasing the plan from 10 million to 13 million shares.
-
Limited Remaining Authorized Shares
If both proposals pass, the company would have only approximately 26 million authorized shares remaining for issuance, excluding shares reserved for outstanding instruments.
-
Chairman's 49.4% Ownership
Chairman Richard Uihlein beneficially owns 54,831,388 shares, representing 49.4% of common stock, after converting $105.8 million of debt to equity on July 31, 2026.
Analysis · GALT · Life Sciences
The proxy asks shareholders to approve a 100 million share increase in authorized common stock, from 150 million to 250 million. With only about 26 million authorized shares remaining after accounting for the equity plan expansion, the company is signaling it will need to raise capital through equity financings after its current cash runway is exhausted. The filing also discloses that Chairman Richard Uihlein now controls 49.4% of the company after converting $105.8 million of debt to equity in July 2026, giving him significant influence over the vote.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GALT was trading at $3.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $394.8M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.